Application effect of establishing prognostic evaluation model based on prognostic nutritional index and total protein, hemoglobin, transferrin levels in patients with liver cancer radiotherapy and chemotherapy

Abstract

Abstract: Objective:To explore the application effect of establishing a prognostic evaluation model based on prognostic nutritional index(PNI) and total protein (TP), hemoglobin (Hb), transferrin (TF) levels in patients with liver cancer radiotherapy and chemotherapy.
Methods:According to enrollment criteria,the research subjects selected a total of 100 patients with liver cancer treated with radiotherapy and chemotherapy in First Affiliated Hospital of Hebei North University from May 2018 to January 2021. According to the prognosis of the patients, they were divided into a stable group (46 cases) and a progressive group (54 cases). The levels of TP, ALB, Hb, and TF were detected, and the PNI was calculated according to their blood biochemical test results. Multivariate Logistic regression was used. The correlation between PNI, TP, Hb, TF levels and patient prognosis was analyzed, and prognostic evaluation model of PNI combined with TP, Hb and TF was established. The final scores of the patient outcome assessment model were observed for different baseline and clinical data, and the predictive value of prognostic evaluation model was assessed using the receiver operating characteristic (ROC) curve.
Results:The PNI, TP and Hb levels of the two groups in the stable group were significantly higher than those in the progressive group, and the TF level was significantly lower than that in the progressive group (all P<0.05). is an independent risk factor affecting the prognosis of patients (all P<0.05); the results of the prognostic evaluation model in patients with age greater than 60 years, the number of tumors greater than 3, and the largest tumor diameter greater than 5 cm were significantly lower (all P<0.05). There was no significant difference in the results (all P>0.05); the results of the prognostic evaluation model in patients with complications, survival less than 1 year, and disease progression were significantly lower (all P<0.05), and there was no statistical difference in the prognostic evaluation model results in patients with recurrence and metastasis. (all P>0.05). ROC curve showed that the cut-off value of the prognostic evaluation model was 0.621, and the predictive sensitivity was 87.04% and the specificity was 86.96%. The area under the curve is 0.913. Conclusion:The prognosis of patients with liver cancer radiotherapy and chemotherapy is closely related to the nutritional index and the levels of TP, Hb and TF, and the nutritional index combined with the levels of TP, Hb and TF to establish a prognostic evaluation model has high sensitivity and specificity for the prognosis evaluation of patients.

Key words: Prognostic nutritional index, Total protein, Hemoglobin, Transferrin, Prognostic evaluation model, Liver cancer, Radiotherapy, Chemotherapy, Prognosis

Ren Dongjing, Ma Haiyan, Guo Fei. Application effect of establishing prognostic evaluation model based on prognostic nutritional index and total protein, hemoglobin, transferrin levels in patients with liver cancer radiotherapy and chemotherapy[J]. Electronic Journal of Liver Tumor, 2023, 10(4): 38-41.

References

[1] 王月波,陈加源.CT及MRI对原发性肝癌经导管肝动脉化疗栓塞术后疗效评估的对比[J].实用医学杂志,2017,33(18):3110-3114.
[2] 张典,姜凤良,胡志芳,等.原发性肝癌的预防措施[J].中国老年学杂志,2018(17):4317-4319.
[3] 杨耕夫, 余松远. 微波消融/阿帕替尼治疗中晚期肝细胞癌的研究进展[J/CD]. 消化肿瘤杂志(电子版), 2019, 11(3):190-194.
[4] PHILLIPS W T, BAO A, BRENNER A J, et al.Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles[J]. Adv Drug Deliv Rev, 2014, 76(4):39-59.
[5] 赵彦,祝淑钗,宋春洋,等. 放疗前预后营养指数对临床Ⅲ期食管癌患者生存的影响分析[J]. 中华放射医学与防护杂志,2021,41(6):426-430.
[6] 谌小春,张真真,谢晓莺,等.预后营养指数与靶向治疗中晚期肝癌患者的预后关系[J].中国临床医学,2021,28(3):476-481.
[7] 翁敏,代正燕,王昆华. 肝癌患者不同疾病状态时的营养治疗[J/CD]. 肿瘤代谢与营养电子杂志,2022,9(1):1-6.
[8] 周健国,黄彪,范文川,等.肝癌患者围手术期营养风险和营养支持状况的研究[J].中国医师进修杂志,2021,44(9):838-841.
[9] 肖慧娟,张明,齐玉梅,等.相位角与原发性肝癌患者营养状况及临床结局的关系[J].肿瘤防治研究,2021,48(5):503-507.
[10] 邹添添,覃伟,朱迎,等. 肝癌免疫微环境与免疫治疗:研究进展与发展趋势[J]. 中国普通外科杂志,2020,29(7):785-797.
[11] 李娟,周丽娟,李海霞,等.预后营养指数对肝癌术后患者病情进展的预测价值[J].中国现代普通外科进展,2020,23(12):992-995.
[12] 吴婧文,于学娟,杨秋安.小野寺预后营养指数与食管鳞癌同步放化疗不良反应的相关性研究[J].中国癌症杂志,2020,30(7):525-530
[13] 朱润,蒋圣军,隋韬,等.血液炎症-营养指标在晚期肝癌患者的预后价值研究[J].结直肠肛门外科,2021,27(S01):45-46.
[14] 李娟,周丽娟,李海霞,等. 预后营养指数对肝癌术后患者病情进展的预测价值[J]. 中国现代普通外科进展,2020,23(12):992-995.

[1]	Liu Shaoqing, Qi Man. Correlation of STAT3 and miR-200 expression with programmed cell death-ligand 1(PD-L1) in liver cancer patients and their role in resistance to PD-L1 inhibitory [J]. Electronic Journal of Liver Tumor, 2023, 10(4): 55-59.
[2]	Yin Li, Guo Wenjie, Yuan Fangqin, Xu Qingyu, Yao Chengyun, He Xia. Research progress of radiotherapy-based comprehensive therapy in primary hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(4): 60-67.
[3]	Li Huimin, Yihebali·Chi, Xu Xiaoying, Tan Huijing. A case of intracranial solitary fibrous tumor/hemangio-pericytoma with multiple liver, lung, and bone metastases [J]. Electronic Journal of Liver Tumor, 2023, 10(4): 68-71.
[4]	Fan Weijun. Summary of research status of vascular intervention for primary liver cancer [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 27-30.
[5]	Tang Fan, Luo Yingen, Ou Aixin, Xu Haoran, Li Xiao. The global status and development trends of radioembolization for liver cancer with yttrium-90: a bibliometric analysis [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 38-47.
[6]	Zhao Ying, Li Kewei, Yang Yanmei, Li Wei, Li Guangxin, Li Gong. Long-term outcomes of radiotherapy combined with immune checkpoint blockade inhibitor and lenvatinib therapy in hepatocellular carcinoma with portal vein tumor thrombus [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 58-63.
[7]	Wang Yu, Tong Liexing, Kang Wanying, Ding Xin, Qian Hesheng. Recognition of bone metastasis driving genes in hepatocellular carcinoma by machine learning and analysis of in external-beam radiotherapy [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 64-75.
[8]	Xin Lingxia, Xu Xin, Zhai Yirui, Deng Min, Chen Bo. The progress of radiotherapy in hepatocellular carcinoma with portal vein tumor thrombus [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 76-82.
[9]	Yang Yongjing, Liu Tingting, Liu Shixin. Research progress of radiotherapy for extrahepatic cholangiocarcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 83-88.
[10]	Pan Wenbing, Lu Yao, Li Yan, Shi Zhuolin, Liu Yudi. Effect of narrative nursing model based on evidence-based medicine on early ambulation and compliance of patient [J]. Electronic Journal of Liver Tumor, 2023, 10(3): 89-92.
[11]	Bian Tao, Qin Feng, Wang Shengjie, Wang Hui, Han Shanshan. Involvement of microRNA-551a in the response mechanism of sorafenib in patients with advanced hepatocellular carcinoma [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 16-26.
[12]	Guo Xuerong, Cao Ling, Zhang Ruifeng, Wang Xinchen, Qiao Nan, Zhang Yongzhen. Analysis of incidence and mortality of liver cancer in Shanxi cancer registries, 2019 [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 27-32.
[13]	Wu Shu, Liu Yan, Zhan Zhengyin, Li Xiaoqing, Liu Zirong, Huang Lihui, Li Caiyun, Wang Jingya, Lu Hong. Analysis of the effect of mouthwash prepared with mannitol on tyrosine kinase receptor inhibitor oral mucosal adverse reactions in patients with liver cancer [J]. Electronic Journal of Liver Tumor, 2023, 10(2): 51-54.
[14]	Sun Dibo, Ma Haiyan, Guo Fei, Wu Xueliang. Relationship between nutritional status and sarcopenia incidence in patients with primary liver cancer [J]. Electronic Journal of Liver Tumor, 2023, 10(1): 25-30.
[15]	Lan Dongmei, Huang Xiaozhun, Ran Yihong, Xu Lin, Huang Zhangkan, Yin Xin, Che Xu, Bi Xinyu, Zhao Jianjun, Wang Shubin. Clinical progress of local treatment for unresectable colorectal liver metastases [J]. Electronic Journal of Liver Tumor, 2023, 10(1): 35-38.